Zura Bio Ltd 8-K

What Happened

• Zura Bio Ltd (ZURA) filed an 8-K reporting that on April 20, 2026 its Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer Eric Hyllengren was separated from the company. The filing states the separation was not related to the company’s financial or operating results or any disagreements about operations or financial/reporting practices.
• On the same date the Board appointed Marlyn Mathew, the company’s Vice President, Finance and Accounting, as the company’s principal accounting officer and principal financial officer.

Key Details

• Separation effective April 20, 2026; Separation Agreement executed April 21, 2026.
• Severance for Mr. Hyllengren: three months of base salary plus reimbursement for COBRA premiums for up to six months (payments contingent on compliance and other employment benefits).
• Ms. Marlyn Mathew’s new annual base salary: $366,415. She is 42, has been VP Finance & Accounting since June 2022, and previously served as Controller and Assistant Controller at Immunovant (2018–2022).
• The filing notes Ms. Mathew has no arrangements or related-party transactions requiring disclosure and no family ties to company directors or officers.

Why It Matters

• Executive changes at the CFO/principal accounting officer level can affect investor confidence in financial leadership and continuity. Zura disclosed the separation was not due to financial/reporting disagreements, and named an internal successor with finance leadership experience.
• The company disclosed the severance terms and the successor’s compensation increase, giving investors clear, concrete details about transition costs and governance continuity.